Thermo Fisher Scientific | TMO - Cash And Equivalent


Thermo Fisher Scientific reported $3.25B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
Agilent USD 1.81B 49M Mar/2026
Becton, Dickinson and Co. USD 708M 105M Jun/2026
Bio Techne USD 209.82M 36.94M Mar/2026
Bio-Rad Laboratories USD 517M 9.8M Jun/2026
Boston Scientific USD 539M 914M Jun/2026
Bruker USD 184.9M 51.5M Jun/2026
Charles River Laboratories USD 192.02M 195K Jun/2026
Danaher USD 4.35B 1.35B Jun/2026
Dentsply International USD 239M 49M Jun/2026
Edwards Lifesciences USD 2.9B 500M Jun/2026
General Electric Aerospace USD 9.35B 1.64B Jun/2026
Henry Schein USD 138M 18M Mar/2026
Illumina USD 1.09B 329M Mar/2026
Intuitive Surgical USD 8.63B 646.3M Jun/2026
IQVIA Holdings USD 1.91B 38M Jun/2026
Laboratory Of America USD 141.8M 839.3M Jun/2026
Medtronic USD 1.15B 135M Dec/2025
Mettler Toledo International USD 51.38M 9.19M Jun/2026
Myriad Genetics USD 115.2M 9.2M Jun/2026
Olympus JPY 147.24B 93.98B Sep/2025
OraSure Technologies USD 160.58M 16.38M Jun/2026
Quest Diagnostics USD 626M 233M Jun/2026
Repligen USD 606.78M 24.13M Jun/2026
Revvity USD 1.02B 162.62M Jun/2026
Stryker USD 3.39B 513M Jun/2026
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Veracyte USD 299.52M 36.38M Jun/2026
Waters USD 539M 77M Jun/2026
Zimmer Biomet Holdings USD 410M 14.2M Jun/2026